260 related articles for article (PubMed ID: 27363490)
21. A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors.
Lee CH; Turbin DA; Sung YC; Espinosa I; Montgomery K; van de Rijn M; Gilks CB
Mod Pathol; 2009 Dec; 22(12):1519-31. PubMed ID: 19734847
[TBL] [Abstract][Full Text] [Related]
22. Patterns of Chromosomal Abnormalities that Can Improve Diagnosis of Uterine Smooth Muscle Tumors.
Holzmann C; Markowski DN; VON Leffern I; Löning T; Bullerdiek J
Anticancer Res; 2015 Dec; 35(12):6445-56. PubMed ID: 26637855
[TBL] [Abstract][Full Text] [Related]
23. Mast cells in smooth muscle tumors of the uterus.
Orii A; Mori A; Zhai YL; Toki T; Nikaido T; Fujii S
Int J Gynecol Pathol; 1998 Oct; 17(4):336-42. PubMed ID: 9785134
[TBL] [Abstract][Full Text] [Related]
24. Recurrent chromosomal aberrations in intravenous leiomyomatosis of the uterus: high-resolution array comparative genomic hybridization study.
Buza N; Xu F; Wu W; Carr RJ; Li P; Hui P
Hum Pathol; 2014 Sep; 45(9):1885-92. PubMed ID: 25033729
[TBL] [Abstract][Full Text] [Related]
25. Lung metastases and subsequent malignant transformation of a fumarate hydratase -deficient uterine leiomyoma.
Ahvenainen T; Khamaiseh S; Alkodsi A; Mehine M; Nevala R; Äyräväinen A; Bützow R; Vahteristo P
Exp Mol Pathol; 2022 Jun; 126():104760. PubMed ID: 35367216
[TBL] [Abstract][Full Text] [Related]
26. Genomic and Epigenomic Profile of Uterine Smooth Muscle Tumors of Uncertain Malignant Potential (STUMPs) Revealed Similarities and Differences with Leiomyomas and Leiomyosarcomas.
Conconi D; Redaelli S; Lissoni AA; Cilibrasi C; Perego P; Gautiero E; Sala E; Paderno M; Dalprà L; Landoni F; Lavitrano M; Roversi G; Bentivegna A
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33557274
[TBL] [Abstract][Full Text] [Related]
27. Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors.
Croce S; Ducoulombier A; Ribeiro A; Lesluyes T; Noel JC; Amant F; Guillou L; Stoeckle E; Devouassoux-Shisheboran M; Penel N; Floquet A; Arnould L; Guyon F; Mishellany F; Chakiba C; Cuppens T; Zikan M; Leroux A; Frouin E; Farre I; Genestie C; Valo I; MacGrogan G; Chibon F
Mod Pathol; 2018 May; 31(5):816-828. PubMed ID: 29327710
[TBL] [Abstract][Full Text] [Related]
28. An immunohistochemical analysis of stathmin 1 expression in uterine smooth muscle tumors: differential expression in leiomyosarcomas and leiomyomas.
Allen MM; Douds JJ; Liang SX; Desouki MM; Parkash V; Fadare O
Int J Clin Exp Pathol; 2015; 8(3):2795-801. PubMed ID: 26045786
[TBL] [Abstract][Full Text] [Related]
29. [Uterine smooth muscle tumors: retrospective epidemiological and pathological study of 2760 cases].
Rammeh-Rommani S; Mokni M; Stita W; Trabelsi A; Hamissa S; Sriha B; Tahar-Yacoubi M; Korbi S
J Gynecol Obstet Biol Reprod (Paris); 2005 Oct; 34(6):568-71. PubMed ID: 16208199
[TBL] [Abstract][Full Text] [Related]
30. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential.
O'Neill CJ; McBride HA; Connolly LE; McCluggage WG
Histopathology; 2007 Jun; 50(7):851-8. PubMed ID: 17543074
[TBL] [Abstract][Full Text] [Related]
31. PD-L1 Expression and Tumor-infiltrating Lymphocytes in Uterine Smooth Muscle Tumors: Implications for Immunotherapy.
Shanes ED; Friedman LA; Mills AM
Am J Surg Pathol; 2019 Jun; 43(6):792-801. PubMed ID: 31009388
[TBL] [Abstract][Full Text] [Related]
32. Benign metastasizing leiomyoma of the lung: clinicopathologic, immunohistochemical, and micro-RNA analyses.
Nuovo GJ; Schmittgen TD
Diagn Mol Pathol; 2008 Sep; 17(3):145-50. PubMed ID: 18382364
[TBL] [Abstract][Full Text] [Related]
33. Fumarate hydratase (FH) deficiency in uterine leiomyomas: recognition by histological features versus blind immunoscreening.
Siegler L; Erber R; Burghaus S; Brodkorb T; Wachter D; Wilkinson N; Bolton J; Stringfellow H; Haller F; Beckmann MW; Hartmann A; Agaimy A
Virchows Arch; 2018 May; 472(5):789-796. PubMed ID: 29332133
[TBL] [Abstract][Full Text] [Related]
34. Uterine smooth muscle tumors other than the ordinary leiomyomas and leiomyosarcomas: a review of selected variants with emphasis on recent advances and unusual morphology that may cause concern for malignancy.
Ip PP; Tse KY; Tam KF
Adv Anat Pathol; 2010 Mar; 17(2):91-112. PubMed ID: 20179432
[TBL] [Abstract][Full Text] [Related]
35. Uterine leiomyosarcomas and benign smooth muscle tumors: usefulness of nuclear DNA patterns studied by flow cytometry.
Tsushima K; Stanhope CR; Gaffey TA; Lieber MM
Mayo Clin Proc; 1988 Mar; 63(3):248-55. PubMed ID: 3343869
[TBL] [Abstract][Full Text] [Related]
36. Identification of a novel diagnostic gene expression signature to discriminate uterine leiomyoma from leiomyosarcoma.
Adams CL; Dimitrova I; Post MD; Gibson L; Spillman MA; Behbakht K; Bradford AP
Exp Mol Pathol; 2019 Oct; 110():104284. PubMed ID: 31301306
[TBL] [Abstract][Full Text] [Related]
37. Pathology, cytogenetics and molecular biology of uterine leiomyomas and other smooth muscle lesions.
Quade BJ
Curr Opin Obstet Gynecol; 1995 Feb; 7(1):35-42. PubMed ID: 7742513
[TBL] [Abstract][Full Text] [Related]
38. MED12 mutations occurring in benign and malignant mammalian smooth muscle tumors.
Markowski DN; Huhle S; Nimzyk R; Stenman G; Löning T; Bullerdiek J
Genes Chromosomes Cancer; 2013 Mar; 52(3):297-304. PubMed ID: 23225304
[TBL] [Abstract][Full Text] [Related]
39. Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling.
Quade BJ; Wang TY; Sornberger K; Dal Cin P; Mutter GL; Morton CC
Genes Chromosomes Cancer; 2004 Jun; 40(2):97-108. PubMed ID: 15101043
[TBL] [Abstract][Full Text] [Related]
40. Morphologic features of prognostic significance in uterine smooth muscle tumors: a review of eighty-four cases.
Burns B; Curry RH; Bell ME
Am J Obstet Gynecol; 1979 Sep; 135(1):109-14. PubMed ID: 474641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
